News
CNTX
1.380
+6.15%
0.080
Weekly Report: what happened at CNTX last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at CNTX last week (0408-0412)?
Weekly Report · 04/15 10:00
Weekly Report: what happened at CNTX last week (0401-0405)?
Weekly Report · 04/08 10:03
CONTEXT THERAPEUTICS SUBMITS IND APPLICATION TO EVALUATE CTIM-76 IN CLAUDIN 6-POSITIVE CANCERS
Reuters · 04/01 11:30
Weekly Report: what happened at CNTX last week (0325-0329)?
Weekly Report · 04/01 10:02
Weekly Report: what happened at CNTX last week (0318-0322)?
Weekly Report · 03/25 10:03
Weekly Report: what happened at CNTX last week (0311-0315)?
Weekly Report · 03/18 10:02
Weekly Report: what happened at CNTX last week (0304-0308)?
Weekly Report · 03/11 10:01
Weekly Report: what happened at CNTX last week (0226-0301)?
Weekly Report · 03/04 10:03
Weekly Report: what happened at CNTX last week (0219-0223)?
Weekly Report · 02/26 10:08
Weekly Report: what happened at CNTX last week (0212-0216)?
Weekly Report · 02/19 10:09
Weekly Report: what happened at CNTX last week (0205-0209)?
Weekly Report · 02/12 10:04
Weekly Report: what happened at CNTX last week (0129-0202)?
Weekly Report · 02/05 10:08
Weekly Report: what happened at CNTX last week (0122-0126)?
Weekly Report · 01/29 10:03
Weekly Report: what happened at CNTX last week (0115-0119)?
Weekly Report · 01/22 10:05
Weekly Report: what happened at CNTX last week (0108-0112)?
Weekly Report · 01/15 10:03
Weekly Report: what happened at CNTX last week (0101-0105)?
Weekly Report · 01/08 10:05
Context Therapeutics Inc: Statement of acquisition of beneficial ownership by individuals
Press release · 01/05 22:22
Weekly Report: what happened at CNTX last week (1225-1229)?
Weekly Report · 01/01 10:02
Weekly Report: what happened at CNTX last week (1218-1222)?
Weekly Report · 12/25/2023 10:08
More
Webull provides a variety of real-time CNTX stock news. You can receive the latest news about Context Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CNTX
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, which is in preclinical development. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window, which is the difference between the dose required for the intended therapeutic effect and the dose required to elicit an unwanted side effect.